Zhou Jing, Jing Ming, Liu Ming, Fang Liya, Yang Luan, Qiao Guizhi
Department of Dermatology, Jinan Dermatosis Prevention and Control Hospital, Jinan, P. R. China.
Department of Dermatology, Zaozhuang Municipal Hospital, Zaozhuang, P. R. China.
J Dermatolog Treat. 2025 Dec;36(1):2562302. doi: 10.1080/09546634.2025.2562302. Epub 2025 Sep 18.
To evaluate the efficacy and safety of apremilast, a phosphodiesterase-4 (PDE-4) inhibitor, in treating pityriasis lichenoides et varioliformis acuta (PLEVA) and explore its potential mechanisms.
We present a 16-year-old male with refractory PLEVA who failed conventional therapies (systemic corticosteroids, acitretin). Treatment with oral apremilast (30 mg twice daily) was initiated.
Significant improvement was observed within 1 week, with near-complete clearance by 8 weeks. No relapse or adverse events occurred during 12-month follow-up.
Apremilast may be a safe and effective option for refractory PLEVA.
评估磷酸二酯酶-4（PDE-4）抑制剂阿普米拉斯治疗急性痘疮样苔藓样糠疹（PLEVA）的疗效和安全性，并探讨其潜在机制。
我们报告一名16岁男性难治性PLEVA患者，其对传统疗法（全身用糖皮质激素、阿维A）无效。开始口服阿普米拉斯（每日两次，每次30毫克）治疗。
1周内观察到显著改善，8周时几乎完全清除。在12个月的随访期间未发生复发或不良事件。
阿普米拉斯可能是难治性PLEVA的一种安全有效的选择。
